Soluble HTLV-I Tax1 protein stimulates proliferation of human peripheral blood lymphocytes.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Soluble HTLV-I Tax1 protein stimulates proliferation of human peripheral blood lymphocytes.

New Biol. 1991 Jul;3(7):678-86. Unique Identifier : AIDSLINE MED/92089024
Marriott SJ; Lindholm PF; Reid RL; Brady JN; Laboratory of Molecular Virology, National Cancer Institute,; Bethesda, MD 20892.

Abstract: Human T-cell leukemia virus type I (HTLV-I) is associated with two human diseases, adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM). Lymphocytes from patients with ATL or TSP/HAM display abnormal proliferation properties in culture. Here we report that purified, soluble Tax1 protein can be taken up by, and stimulate proliferation of, uninfected human peripheral blood lymphocytes (PBLs) that have been stimulated with phytohemagglutinin (PHA). Tax1 was 40 to 70% as active as interleukin-2 (IL-2) in stimulating proliferation of PBLs. Heat inactivation, chloroform extraction, and immunoprecipitation with antisera specific for Tax1 each abolished the ability of the protein to stimulate lymphocyte proliferation. Tax1 failed to stimulate PBL proliferation in the absence of PHA. After an initial round of cell division, Tax1-treated PBLs exhibited prolonged sensitivity to IL-2-induced proliferation. These results indicate that Tax1 can stimulate lymphocyte proliferation in culture and imply that extracellular Tax1 may be involved in the spontaneous proliferation of TSP/HAM lymphocytes and the IL-2-dependent proliferation of ATL lymphocytes.

Keywords: Blotting, Western Cell Division/DRUG EFFECTS Chloramphenicol Acetyltransferase/BIOSYNTHESIS Chloroform/PHARMACOLOGY Drug Interactions Gene Expression Regulation, Viral Gene Products, tax/*PHARMACOLOGY/PHARMACOKINETICS Heat/ADVERSE EFFECTS Human In Vitro Interleukin-2/PHARMACOLOGY Leukemia, T-Cell Lymphocyte Transformation/*DRUG EFFECTS Lymphocytes/METABOLISM Phytohemagglutinins Time Factors Trans-Activation (Genetics) JOURNAL ARTICLE
920430
M9240919

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .